- cafead Oct 24, 2023 at 10:12: AM
via Sanofi has reported positive data from a Phase III clinical trial of Dupixent (dupilumab) in children aged one to 11 years with eosinophilic oesophagitis (EoE).
The double-blind, placebo-controlled, randomised trial assessed the safety and efficacy of Dupixent for up to 52 weeks.
article source
The double-blind, placebo-controlled, randomised trial assessed the safety and efficacy of Dupixent for up to 52 weeks.
article source